RT Journal Article
SR Electronic
T1 Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20202861
DO 10.1101/2020.09.28.20202861
A1 Zhu, Yuyu
A1 Shao, Fenli
A1 Yan, Wei
A1 Chen, Zhen Bouman
A1 Ke, Bowen
A1 Jiang, Xian
A1 Cheng, Haibo
A1 Sun, Dongdong
A1 Song, Chenglin
A1 Kong, Lingdong
A1 Guo, Wenjie
A1 Lai, Yuping
A1 Feng, Gen-Sheng
A1 Xu, Qiang
A1 Sun, Yang
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.28.20202861.abstract
AB Psoriasis is a complex chronic inflammatory skin disease with unclear molecular mechanisms. Here, we identify Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) as a novel accelerator of psoriasis development. Both genetic ablation of SHP2 in macrophages and pharmacological inhibition of SHP2 prevents the development of psoriasis-like skin inflammation in an imiquimod-induced murine model of psoriasis. Mechanistically, SHP2 promotes the trafficking of Toll-like receptor 7 (TLR7) from Golgi to endosome through its interaction with and dephosphorylation of TLR7 at Tyr1024, which promotes the ubiquitination of TLR7 and psoriasis-like skin inflammation. Importantly, SHP2 allosteric inhibitor SHP099 reduces the expression of pro-inflammatory cytokines in peripheral blood mononuclear cells from human patients with psoriasis. Collectively, our findings identify SHP2 as a novel regulator of psoriasis and suggest that SHP2 inhibition may be a promising therapeutic approach for psoriatic patients.Competing Interest StatementY.S. and Q.X. have a patent pending on use of SHP2 inhibitors in psoriasis (202010109716.0). The other authors declare no conflict of interest.Funding StatementThis work was supported by National Natural Science Foundation of China (Nos. 81872877, 81730100, 91853109, 81673436, 81803142), and Mountain-Climbing Talents Project of Nanjing University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Animal welfare and experimental procedures were approved by the Institutional Animal Care and Use Committee at Nanjing University. All human studies were approved by the Ethics Institutional Review Board of West China Hospital, Sichuan University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data have been deposited to the Gene Expression Omnibus with accession no. GSE147535. All other data needed to evaluate the conclusions in this manuscript are present in the paper.